Search results
Results from the WOW.Com Content Network
15–50% (with sudden stopping) [3] [4] Antidepressant discontinuation syndrome , also called antidepressant withdrawal syndrome , is a condition that can occur following the interruption, reduction, or discontinuation of antidepressant medication following its continuous use of at least a month. [ 5 ]
Like other SSRIs, sertraline is associated with sexual side effects, including sexual arousal disorder, erectile dysfunction and difficulty achieving orgasm. While nefazodone and bupropion do not have negative effects on sexual functioning, 67% of men on sertraline experienced ejaculation difficulties versus 18% before the treatment. [ 92 ]
One of the most widely prescribed antidepressants, sertraline, also known by brand names Zoloft and Lustral, was associated with an average gain of nearly 0.5 pounds (0.2 kilograms) at six months.
Some side effects, such as weight gain, occur more frequently with certain types of antidepressant medication. Switching to a new type of antidepressant may help reverse any weight gain you’ve ...
This is a complete list of clinically approved prescription antidepressants throughout the world, as well as clinically approved prescription drugs used to augment antidepressants or mood stabilizers, by pharmacological and/or structural classification.
The severity of effects alcohol may have on a developing fetus depends upon the amount and frequency of alcohol consumed as well as the stage of pregnancy. Rates of alcohol consumption can generally be categorized in one of three ways: heavy drinking (more than 48-60 grams of ethanol/day), moderately high drinking (24-48 grams of ethanol/day ...
Lexapro, Paxil and Cymbalta carry a higher risk of packing on pounds than Zoloft, while Wellbutrin users are less likely to gain weight, according to a new study of eight popular antidepressants.
It combines serotonin reuptake inhibition from sertraline and modulation of dopamine and serotonin receptors from aripiprazole. [1] [2] In July 2017, it was in preregistration in Japan for the treatment of MDD. [1] However, in September 2018, the regulatory submission in Japan for MDD was withdrawn. [3]